MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series
Abstract Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the ris...
Saved in:
Main Authors: | Rodolfo Mauceri (Author), Martina Coppini (Author), Massimo Attanasio (Author), Alberto Bedogni (Author), Giordana Bettini (Author), Vittorio Fusco (Author), Amerigo Giudice (Author), Filippo Graziani (Author), Antonia Marcianò (Author), Marco Nisi (Author), Gaetano Isola (Author), Rosalia Maria Leonardi (Author), Giacomo Oteri (Author), Corrado Toro (Author), Giuseppina Campisi (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single Center Retrospective Cohort Study
by: Rodolfo Mauceri, et al.
Published: (2022) -
Oral Squamous Cell Carcinoma Mimicking Medication-Related Osteonecrosis of the Jaws (MRONJ): A Case Series
by: Rodolfo Mauceri, et al.
Published: (2021) -
Temporary Denosumab Discontinuation Promotes Bone Healing of Osteonecrosis of the Jaw and Minimizes the Invasiveness of Surgery: A Case Presentation
by: Giordana Bettini, et al.
Published: (2022) -
Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review
by: Rodolfo Mauceri, et al.
Published: (2024) -
DOXYCYCLINE BONE LABELING - IMPACT ON MRONJ TREATMENT
by: Vlad Daniel, et al.
Published: (2022)